Biomerica Reports First Quarter Fiscal 2026 Financial Results

• Reported Improved Gross Margin from Contribution from Higher-Margin Product Mix
  
  
• Operating Expenses Continued to Decline Compared to the First Quarter of the Prior Fiscal Year, Reflecting the Company’s Ongoing Focus on Cost Reduction and Operational Efficiency
  
  
• Earnings per Share $0.00, Compared to a Net Loss of $0.08 per Share in the First Quarter of the Prior Fiscal Year.
  

IRVINE, Calif., Oct. 15, 2025 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), ("Biomerica" or the "Company") a global provider of advanced medical diagnostic and therapeutic products today reported financial results for the first quarter ended August 31, 2025.

Key Highlights:

1. inFoods IBS receives Proprietary Laboratory Analysis ("PLA") Code
   
   The American Medical Association CPT Editorial Panel has issued a PLA code for the Biomerica's inFoods IBS test. This newly granted PLA code serves as a unique identifier for the test, allowing healthcare providers and Biomerica’s laboratory partner to submit claims to Medicare and private insurers once reimbursement price is set by the Centers for Medicare & Medicaid Services. The PLA code represents a next step on the pathway to expand patient access to the inFoods IBS product through a billable reimbursement code.
   
   
2. United Arab Emirates ("UAE") Ministry of Health and Prevention Approves Biomerica’s Fortel Ulcer Test for Home Use 
   
   The UAE Ministry of Health and Prevention has approved Biomerica’s Fortel Ulcer Test for home use, marking an important milestone in expanding access to accurate, easy-to-use diagnostic tools for one of the leading causes of gastric disease in the region. The Fortel Ulcer Test is a rapid, 10-minute diagnostic test that detects antibodies to Helicobacter pylori ("H. pylori"), a bacterium responsible for peptic ulcers, dyspepsia, and a significant portion of gastric cancer cases. With this new regulatory approval, individuals across the UAE can now self-administer the test in the comfort and privacy of their own homes. A 2019 study found that H. pylori affects approximately 41% of the UAE population, with higher prevalence among certain age and ethnic groups. If left untreated, up to 20% of infected individuals may develop serious complications such as peptic ulcers, chronic digestive pain, or gastric malignancies. Notably, up to 80% of gastric cancer cases are linked to H. pylori infection, making it one of the most significant infectious cancer risk factors worldwide.